Keppra
Psychosomatic Disorders
Hannover Medical SchoolPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Psychosomatic Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acamprosate Hannover Medical School | Phase 3 | B |
Risperdal Hannover Medical School | Phase 3 | B |
Oxcarbamezapine Hannover Medical School | Phase 3 | B |
Paliperidone Palmitate 3-Month Formulation Hannover Medical School | Phase 3 | B |
Promethazine Hannover Medical School | Phase 3 | B |
View all 50 →
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →